Pulmonary safety and tolerability of inhaled levodopa (CVT-301) administered to patients with Parkinson’s disease

Tuesday, January 25th, 2022

These two randomized controlled trials evaluated pulmonary function in patients with Parkinson’s disease treated with single-dose inhaled CVT-301 or placebo (study 1) or multiple-doses of inhaled CVT-301/day or placebo for 4 weeks (study 2). In both studies, pre- and post-dose lung function testing (FEV1, FVC, FEV1/FVC ratio) was undertaken using a Vitalograph Pneumotrac spirometer.